Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA:688091)

Market Cap	8.52B -3.3%
Revenue (ttm)	324.20M +84.4%
Net Income	68.54M
EPS	0.34
Shares Out	204.80M
PE Ratio	122.27
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,540,007
Open	41.00
Previous Close	41.58
Day's Range	39.90 - 41.43
52-Week Range	39.90 - 83.60
Beta	-0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About SHA:688091

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2009
• Employees: 415
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688091

Financial Performance

In 2025, SHA:688091's revenue was 316.08 million, an increase of 82.14% compared to the previous year's 173.53 million. Earnings were 64.56 million, an increase of 825.49%.